9 completed, 3 withdrawn, 2 terminated. 4 Phase 4, 3 Phase 3, 2 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 4 | Completed 2, Terminated 1, Withdrawn 1 |
| Phase 3 | 3 | Completed 2, Terminated 1 |
| Not applicable | 2 | Completed 1, Withdrawn 1 |
| Phase 1 | 1 | Completed 1 |
Follow recombinant factor VIII SQ: new trials by email Literature Review of recombinant factor VIII SQ trials Research Report on recombinant factor VIII SQ
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Patient-reported Outcomes in Subjects Treated With ReFacto AF Routine Prophylaxis Refacto AF - Hemophilia A | Withdrawn | Pfizer | 2019-09-01 | 2020-11-16 | ||
| Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha® In Subjects With Hemophilia A Xyntha : coagulation factor IIIV (recombinant) - Hemophilia A | Completed | Pfizer | 42 | 2014-02-01 | 2015-08-17 | |
| Relative Bioavailability Of Two Formulations Of Moroctocog Alfa (AF-CC) moroctocog alfa (AF-CC) - Hemophilia A | Phase 1 | Completed | Pfizer | 16 | 2012-08-01 | 2013-02-08 |
| Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients Moroctocog alfa ( AF-CC), Laboratory tests - Hemophilia A | Phase 4 | Completed | Pfizer | 37 | 2009-12-01 | 2017-02-10 |
| Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive FVIII Concentrates, FVIII/VWF concentrates - Severe Hemophilia A | Not applicable | Withdrawn | City of Hope Medical Center | 2009-09-25 | 2020-12-17 | |
| Study Evaluating Pharmacovigilance Of Refacto AF ReFacto AF (Moroctocog alfa) - Hemophilia A | Completed | Pfizer | 101 | 2009-07-17 | 2018-07-17 | |
| Study Evaluating The Efficacy And Safety Of Xyntha In Children Less Than 6 Years Of Age Moroctocog alfa - Hemophilia A | Phase 3 | Terminated | Wyeth is now a wholly owned subsidiary of Pfizer | 1 | 2009-06-01 | 2022-06-15 |
| Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care Settings moroctocog alfa (AF-CC) (ReFacto AF), Laboratory tests - Hemophilia A | Phase 4 | Terminated | Pfizer | 208 | 2009-05-01 | 2014-09-01 |
| Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII Moroctocog alfa (AF-CC) - Hemophilia A | Phase 3 | Completed | Pfizer | 66 | 2007-12-01 | 2019-01-11 |
| Clot Formation and Clot Stability in Patients With Severe Haemophilia A ReFacto (Recombinant factor VIII) and Tranexamic acid - Hemophilia A | Not applicable | Completed | University of Aarhus | 8 | 2006-01-01 | 2006-11-16 |
| Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A ReFacto AF, B-Domain deleted Recombinant Factor VIII, BDDrFVIII - Hemophilia A | Phase 3 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 100 | 2005-07-01 | 2008-04-22 |
| Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A ReFacto, Advante - Hemophilia A | Phase 4 | Withdrawn | Wyeth is now a wholly owned subsidiary of Pfizer | 2005-04-01 | 2018-09-25 | |
| Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery ReFacto - Hemophilia A | Phase 4 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 15 | 2003-02-01 | 2007-12-28 |
| Study Evaluating Refacto For Pharmacovigilance Moroctocog alfa - Hemophilia A | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 288 | 1999-07-01 | 2011-02-11 |
Hemophilia A (14) · Hemostatic Disorders (1)
Pfizer (7) · Wyeth is now a wholly owned subsidiary of Pfizer (5) · City of Hope Medical Center (1) · University of Aarhus (1)
Germany (5) · Austria (4) · Italy (4) · United States (4) · Belgium (3) · Finland (3) · France (3) · Hungary (3) · Netherlands (3) · New Zealand (3) · Romania (3) · Spain (3) · Sweden (3) · United Kingdom (3) · Denmark (2)
Anne-Mette Hvas, MD, Ph.D. (1) · Nadia P Ewing, MD (1)
2008 (2)